Welcome to our dedicated page for Crescita Therape news (Ticker: CRRTF), a resource for investors and traders seeking the latest updates and insights on Crescita Therape stock.
Crescita Therapeutics Inc. (CRRTF) is a biotechnology leader focused on developing innovative therapeutic solutions through advanced research and strategic collaborations. This page serves as a centralized hub for all official company announcements, regulatory updates, and progress in drug development.
Investors and industry professionals will find timely updates on clinical trial milestones, partnership agreements, and R&D advancements. Our curated collection ensures transparent access to Crescita's latest developments in pharmaceutical innovation, including licensing deals and regulatory submissions.
Key updates include progress in therapeutic pipelines, intellectual property developments, and financial performance reports. Bookmark this page to stay informed about Crescita's contributions to biotechnology and its evolving position in global healthcare markets.
Crescita Therapeutics announced the results from its Annual General and Special Meeting of Shareholders held on June 5, 2024, in Laval, Quebec. Key outcomes included the election of directors with strong support ranging from 98.3% to 99.9% approval. Daniel N. Chicoine, Anthony E. Dobranowski, John C. London, Deborah Shannon-Trudeau, and Serge Verreault were elected as directors. Ernst & Young LLP was reappointed as the external auditor with 98.0% approval. The company's Share Incentive Plan was also approved with 98.9% votes in favor.
Crescita Therapeutics Inc. reported its financial results for the first quarter of 2024, showing an increase in revenue to $4,996 compared to $4,602 in Q1-2023. However, gross profit decreased to $2,411 from $2,736, and Adjusted EBITDA fell to $(325) from $161. The Company is focusing on the Skincare segment, launching new products and expanding internationally.
Crescita Therapeutics (CRRTF) reported a record annual revenue of $23.5M for fiscal year 2022, a 40% increase from 2021. Adjusted EBITDA rose by 138% to $2.2M. In Q4 2022, revenue was $6.03M, a 20% decline from Q4 2021, primarily due to lower licensing revenues. However, gross profit for the year grew 32% to $13.18M despite a slight decrease in gross margin. Cash reserves fell to $8.23M from $11.33M. The company launched ART FILLER in Q1 2023, aiming to enhance its skincare portfolio. Management highlighted growth in the manufacturing segment and successful product launches.
